文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

心肌纤维化在糖尿病性心肌病中的作用。

The role of myocardial fibrosis in the diabetic cardiomyopathy.

作者信息

Sun Jinghui, Zhou Ruiling, Liu Mi, Zhang Dawu

机构信息

National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 10091, China.

出版信息

Diabetol Metab Syndr. 2025 Jun 24;17(1):242. doi: 10.1186/s13098-025-01783-9.

DOI:10.1186/s13098-025-01783-9
PMID:40551185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12186413/
Abstract

Diabetic cardiomyopathy (DCM), a main cardiovascular complication of diabetes mellitus, can eventually develop into heart failure and seriously affect the prognosis of diabetic patients. Myocardial fibrosis (MF) is the main factor causing ventricular wall stiffness and heart failure in DCM. Early control of MF in DCM is of great significance to prevent or postpone the progression of DCM to heart failure. In this review, we systematically analyzed the relevant studies on diabetic MF in recent years, explored the formation mechanism of MF in the pathological process of DCM, and summarized and analyzed in detail the current studies with antifibrotic treatment for DCM, so as to provide guidance for the development of prevention and treatment strategies for MF in DCM.

摘要

糖尿病性心肌病（DCM）是糖尿病的主要心血管并发症，最终可发展为心力衰竭，严重影响糖尿病患者的预后。心肌纤维化（MF）是导致DCM患者心室壁僵硬和心力衰竭的主要因素。早期控制DCM中的MF对于预防或延缓DCM进展为心力衰竭具有重要意义。在本综述中，我们系统分析了近年来关于糖尿病性MF的相关研究，探讨了DCM病理过程中MF的形成机制，并详细总结和分析了目前针对DCM进行抗纤维化治疗的研究，以期为DCM中MF防治策略的制定提供指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/bbd55f881b8a/13098_2025_1783_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/3071a614dc1e/13098_2025_1783_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/dbbcf8498018/13098_2025_1783_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/3b6109034547/13098_2025_1783_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/bbd55f881b8a/13098_2025_1783_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/3071a614dc1e/13098_2025_1783_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/dbbcf8498018/13098_2025_1783_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/3b6109034547/13098_2025_1783_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabb/12186413/bbd55f881b8a/13098_2025_1783_Fig4_HTML.jpg

相似文献

[1]
The role of myocardial fibrosis in the diabetic cardiomyopathy.

Diabetol Metab Syndr. 2025-6-24

[2]
Trapidil attenuates diabetic cardiomyopathy via GPX3/Nrf2-mediated inhibition of myocardial pyroptosis.

Front Pharmacol. 2025-6-3

[3]
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.

Cochrane Database Syst Rev. 2022-2-24

[4]
Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes.

Cochrane Database Syst Rev. 2021-2-8

[5]
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.

Cochrane Database Syst Rev. 2022-9-27

[6]
Environmental Risk Factors Are Associated With the Natural History of Familial Dilated Cardiomyopathy.

J Am Heart Assoc. 2025-5-6

[7]
Ferroptosis: A novel therapeutic target for diabetic cardiomyopathy.

World J Diabetes. 2025-6-15

[8]
Sex Differences in the Clinical Presentation and Natural History of Dilated Cardiomyopathy.

JACC Heart Fail. 2024-2

[9]
Beta-blockers in patients without heart failure after myocardial infarction.

Cochrane Database Syst Rev. 2021-11-5

[10]
Glucose targets for preventing diabetic kidney disease and its progression.

Cochrane Database Syst Rev. 2017-6-8

本文引用的文献

[1]
Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms.

Diabetol Metab Syndr. 2024-9-18

[2]
The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?

J Am Coll Cardiol. 2024-7-9

[3]
Atorvastatin ameliorated myocardial fibrosis in db/db mice by inhibiting oxidative stress and modulating macrophage polarization.

World J Diabetes. 2023-12-15

[4]
Ultrasound-targeted semaglutide-loaded PEG-nanoliposomes microbubble destruction protects diabetic cardiomyopathy by activating PI3K/Akt/Nrf2 signaling pathway.

Heliyon. 2023-9-7

[5]
Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus.

Diabetol Metab Syndr. 2023-4-29

[6]
Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP.

Drug Des Devel Ther. 2023

[7]
The Protective Effect of Sheng Mai Yin on Diabetic Cardiomyopathy via NLRP3/Caspase-1 Pathway.

Evid Based Complement Alternat Med. 2022-12-1

[8]
The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB-mediated inflammatory response.

Biomed Pharmacother. 2023-1

[9]
LncRNA TUG1 Exacerbates Myocardial Fibrosis in Diabetic Cardiomyopathy by Modulating the microRNA-145a-5p/Cfl2 Axis.

J Cardiovasc Pharmacol. 2023-3-1

[10]
STAMP2 Attenuates Cardiac Dysfunction and Insulin Resistance in Diabetic Cardiomyopathy via NMRAL1-Mediated NF-κB Inhibition in Type 2 Diabetic Rats.

Diabetes Metab Syndr Obes. 2022-10-20

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索